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Diabetic nephropathy is a serious complication of diabetes mellitus, and its prevalence has been increasing worldwide. Therefore,
there is an urgent need to identify a new therapeutic target to prevent diabetic nephropathy. Autophagy is a major catabolic
pathway involved in degrading and recycling macromolecules and damaged organelles to maintain intracellular homeostasis. The
study of autophagy in mammalian systems is advancing rapidly and has revealed that it is involved in the pathogenesis of various
metabolic or age-related diseases. The functional role of autophagy in the kidneys is also currently under intense investigation
although, until recently, evidence showing the involvement of autophagy in the pathogenesis of diabetic nephropathy has been
limited. We provide a systematic review of autophagy and discuss the therapeutic potential of autophagy in diabetic nephropathy
to help future investigations in this ﬁeld.
1.Introduction
The prevalence of diabetes mellitus has been increasing
worldwide during recent years, and this is estimated to con-
tinue in the future [1, 2]. Diabetic nephropathy is a serious
complication of diabetes mellitus and is the most common
cause of end-stage renal disease [3, 4]. The increasing preva-
lence of diabetes mellitus and its complications, including
diabetic nephropathy, has therefore become a major health
problem worldwide. There is now an urgent need to identify
new therapeutic target molecules or cellular processes that
underlie the pathogenesis of diabetic nephropathy to estab-
lish an additional therapeutic option.
Hyperglycemia-mediated alteration of extra- and intra-
cellular metabolism, such as advanced glycation end prod-
ucts [5], increased protein kinase C activity [6], and ab-
normal polyol metabolism [7], has been recognized as clas-
sical pathogenesis of diabetic nephropathy. In addition, in-
tracellular stress associated with renal hypoxia [8, 9], mi-
tochondrial reactive oxygen species (ROS) [10–13], and
endoplasmic reticulum (ER) stress [14–16]h a sr e c e n t l yb e e n
proposed and focused as new pathogenesis of diabetic neph-
ropathy. Thus, to maintain the cellular homeostasis against
stress condition derived from organelle dysfunction or hyp-
oxiamaybeanewtherapeutictargetofdiabeticnephropathy.
Autophagy, a lysosomal protein degradation pathway in
cells, plays a crucial role in removing protein aggregates as
wellasdamagedorexcessorganellestomaintainintracellular
homeostasis and cell integrity [17]. It has recently been
highlighted because it can be stimulated by multiple types
of cellular stressors including starvation, hypoxia, or ER
stress. The study of autophagy in mammalian systems and
in disease states is advancing rapidly, and many investigators
are entering this new and exciting ﬁeld (Figure 1). It has
been revealed that autophagy plays a crucial role in several
organs, especially in metabolic organs, and that its alteration
isinvolvedinthepathogenesisofmetabolic[18–21]andage-
related diseases [22–27]. The functional role of autophagy
in the kidneys is currently under intense investigation
(Figure 1), and it has been revealed that autophagy has a
renoprotective role in several animal models including those
usedforagingandacutekidneyinjury[26–31].However,the
role of autophagy in diabetic nephropathy remains unclear.
Alteration of several nutrient-sensing pathways is related
to the development of metabolic diseases, such as type 2 dia-
betes and its vascular complications. Major nutrient-sensing2 Experimental Diabetes Research
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Figure 1: Substantial increases in the number of autophagy-related
papers indexed in PubMed/Medline. The number of autophagy-
related papers in all ﬁelds has increased remarkably over recent dec-
ades. Corresponding with the increase of autophagy-related papers
in all ﬁelds, publication of autophagy-related papers in nephrology
ﬁelds, also gradually increased.
pathway involves the mammalian target of rapamycin
(mTOR) [32–35], AMP-activated protein kinase (AMPK),
[36–40] and oxidized NAD- (NAD+-) dependent histone
deacetylase (Sirt1) [41–43], which are also recognized as
the regulatory factors of autophagy under nutrient-depleted
condition. As described above, autophagy can be induced by
intracellular stresses that are involved in the pathogenesis of
diabeticnephropathy[44].Thus,alterationofthesenutrient-
sensing pathways under diabetic condition may impair the
autophagic stress response stimulated by intracellular stress,
which may lead to exacerbation of organelle dysfunction and
subsequent diabetic nephropathy.
The above ﬁndings lead us to hypothesize that autophagy
is involved in the pathogenesis of diabetic nephropathy and
is a potential therapeutic option. Therefore, we provide a
systematic review of autophagy and discuss its therapeutic
potencyindiabeticnephropathytohelpfutureinvestigations
in this ﬁeld.
2. Autophagy
The term autophagy is derived from Greek and means self-
eating. It is highly conserved from yeast to mammals and is
a bulk degradation process that is involved in the clearance
of long-lived proteins and organelles. Autophagy has two
major roles in cells: to recycle intracellular energy resources
in response to nutrient-depleted conditions and to remove
cytotoxic proteins and organelles under stressful conditions.
Autophagy works to maintain cell homeostasis under var-
ious stressful conditions. Several types of autophagy have
been recognized in cells: macroautophagy, microautophagy,
and chaperone-mediated autophagy; these diﬀer in their
mechanisms and functions [45, 46]. Of these three types of
autophagy, macroautophagy is most prevalent and hereafter
is referred to as autophagy. In this paper, we focus on the
mechanisms and functions of autophagy.
3.MolecularMechanisms ofAutophagy
Duringmacroautophagy,denovoisolationmembranes(pha-
gophores) elongate and fuse while engulﬁng a portion of the
cytoplasm within double-membraned vesicles (autophago-
somes) (Figure 2). Several origins of autophagosomes have
been reported, including the ER [47–49], mitochondria [50],
and plasma membrane [51]. Four major steps are involved
in the formation of autophagosomes: initiation, nucleation,
elongation, and closure. During these steps, autophagy-
related proteins are involved (Figure 2). Autophagy is initi-
ated by the unc-51-like kinase (Ulk) 1 (mammalian ortholog
of the yeast autophagy-related genes (Atg)1) complex, which
is composed of Ulk1 Ser/Thr protein kinase, Atg13, and
FIP200 (mammalian homolog of the yeast Atg17) [52–
54]. The phosphorylation of Atg13 and FIP200 by Ulk1 is
essential for triggering autophagy. Phagophore nucleation is
dependent on Beclin 1 (Atg6 in yeast)—an hVps34 or class
III phosphatidylinositol 3-kinase (PI3K) complex, which
consists of hVps34, hVps15, Beclin 1, and Atg14 [55, 56].
During autophagosome elongation/closure, two depen-
dent ubiquitin-like conjugation systems are involved: Atg12
and LC3 (the mammalian ortholog of the yeast Atg8) [57].
The Atg12-Atg5 conjugate, which forms the Atg12-Atg5-
Atg16 complex, contributes to the stimulation and localiza-
tion of the LC3 conjugation reaction. The cytosolic isoform
of LC3 (LC3-I) is conjugated to phosphatidylethanolamine
through two consecutive ubiquitination-like reactions that
are catalyzed by E1-like enzyme Atg7 and the E2-like
enzyme Atg3 to form LC3-II [58]. Thus, LC3-II formation
is recognized as a marker of existence of autophagosomes
in cell or animal experiments [59–61]. After formation, the
autophagosomes merge with the lysosomal compartment
to form autolysosomes. The protein p62, also known as
sequestosome 1 (SQSTM1), is known to localize to au-
tophagosomes via LC3 interaction and to be constantly
degraded by the autophagy-lysosome system [62, 63]. The
accumulation of p62 is observed in autophagy-deﬁcient cells
[62, 63].
4. Methods Available for Monitoring Autophagy
It is necessary to keep in mind several important points
as we monitor and assess the autophagy activity to pre-
vent misconceptions. Some reviews about the methods for
autophagy research have been published [59–61]. As brief-
ly below summarized, some methods including electron
microscopy (EM), detection of endogenous LC3 or green
ﬂuorescent protein (GFP)-LC3 by ﬂuorescence microscopy,
and detection of LC3-II by Western blotting are useful
in monitoring the number of autophagosomes. However,
these methods have some limitations. An accumulation of
autophagosomes does not always mean increased formation
of autophagosomes and may represent inhibited matura-
tion of autolysosomes (or amphisomes). Simply countingExperimental Diabetes Research 3
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Figure 2: Scheme of autophagic pathways. Autophagic pathways consist of four steps: initiation, nucleation, elongation, and closure.
Autophagy is initiated by the nucleation of an isolation membrane (phagophore). The phagophore elongates and closes on itself to form
an autophagosome. Fusion of an autophagosome with a lysosome forms an autolysosome and, where the acid hydrolases in the lysosome,
breaks down the inner membrane and cytoplasmic contents.
the number of autophagosomes is insuﬃcient for assess-
ing autophagy activity. Autophagy ﬂux is a term that repre-
sents a serial process of autophagy, including the synthesis
of autophagosomes, the delivery of cargo to lysosomes, and
the degradation of autolysosomes. To distinguish whether
the accumulation of autophagosomes is caused by induction
of autophagy or inhibition of autophagosome maturation
and/ordegradationofautophagicsubstratesinthelysosome,
and then assess autophagy activity, an autophagy ﬂux assay is
more reliable than counting the number of autophagosomes.
There are some useful assays to monitor autophagy ﬂux.
These include the LC3 turnover assay, or measurement of
total levels of autophagic substrates such as LC3, GFP-LC3,
and p62. Furthermore, several types of autophagy inhibitors
a n da c t i v a t o r sh a v er e c e n t l yb e c o m ea v a i l a b l et om o d u -
late the activity of autophagy processes. Pharmacological
inhibitors of autophagy are PI3-kinase inhibitors such as
wortmannin, LY294002, or 3-methladenine (3-MA) and
inhibitors that block autophagosome-lysosome fusion or
degradation of autophagic cargo in autolysosomes, such as
E64d, pepstatin A, and baﬁlomycin A. However, a major
problem is that there are no highly speciﬁc inhibitors or
activators of autophagy. Thus, it is strongly recommended
that pharmacological studies should be combined with
studies that investigate deﬁciency/reduction of autophagy-
related genes by genetic knockout/knockdown of ATG genes
or dominant-negative mutant autophagy proteins, including
Atg3, Atg5, Atg7, and Beclin 1.
5. Role of Nutrient Stress in Autophagy
andDiabeticN e p hr o path y
The kidney is a structurally complex organ and is essential in
severalfunctionsincludingexcretionofthewasteproductsof
metabolism, regulation of body ﬂuid volume, maintenance
of appropriate acid balance, and secretion of a variety of
hormones.Thebasicunitofthekidneyisthenephron,which
consists of a glomerulus and a series of tubules lined by a
continuous layer of epithelial cells (Figure 3). The glomeru-
lus consists of mesangial cells and a capillary wall with
endothelial cells, glomerular basement membrane, and vis-
ceral epithelial cells (podocytes) (Figure 3). Among them,
since podocytes play essential role to maintain glomerular
ﬁltration barrier, podocyte injury leads to proteinuria and
glomerulosclerosis, which are major features of diabetic
nephropathy. Podocytes are terminally diﬀerentiated cells
with a limited proliferative capacity. Therefore, the fate of
podocyte depends on its ability to cope with stress. Excess
ﬂuid ﬁltered through glomerulus enters urinary space and
is reabsorbed by the proximal tubular cells (Figure 3). The
proximal tubular cells serve as a system to degrade several
molecules reabsorbed from urinary space. Thus, autophagy
maybeessentialtomaintaintheirhomeostasisandfunctions
inbothpodocytesandproximaltubularcells,whichmightbe
altered in diabetic condition. If autophagy system is altered
in diabetic condition, this alteration of autophagy may be
involved in the pathogenesis of diabetic nephropathy.
As expected, autophagy has been identiﬁed in both
podocytes and proximal tubular cells and is regulated by a
variety of stimuli including nutrient stress. Nutrient deple-
tion is the most potent physiological inducer of autophagy,
amongseveralthathavebeenreportedtoregulateautophagy.
Here, we show the roles of mTOR, AMPK, and Sirt1, in the
regulation of autophagy. The alteration of these pathways
is involved in the pathogenesis of several kidney diseases
including diabetic nephropathy.
5.1. mTOR. Several studies have shown that hyperactivation
ofthemTORpathwayindiabeticnephropathyplaysapivotal
role in the hypertrophy of existing glomerular and tubular
cells [64, 65] and is associated with podocyte injury and the
progressivedeclineofglomerularﬁltrationrates.Otherstud-
ies have suggested that inhibition of the mTORC1 pathway
with rapamycin has renoprotective eﬀects on the progression
of diabetic nephropathy in models of type 1 [33]a n dt y p e2
diabetes [32, 66–69]. Some reports have shown the additive
renoprotective eﬀects of rapamycin treatment including pre-
vention of mesangial expansion and glomerular membrane
thickness in type 1 diabetic rats [33] and attenuation of
increased glomerular expression of laminin-β1 protein in
type 2 diabetic mice [32, 67]. It has been reported that
activation of the mTOR pathway is involved in the increased
expression of proﬁbrotic cytokines, such as TGF-β1a n d
connective tissue growth factor, and subsequent interstitial
ﬁbrosisindiabeticnephropathy[32–34].Furthermore,more4 Experimental Diabetes Research
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Figure 3: Schematic representation of nephron. The basic unit of the kidney is the nephron, which consists of a glomerulus and a series of
tubules lined by a continuous layer of epithelial cells. The glomerulus consists of mesangial cells and a capillary wall with endothelial cells,
glomerular basement membrane, and visceral epithelial cells (podocytes). Fluid containing albumins and waste products is ﬁltered through
glomerulus, enters urinary space, and is reabsorbed by the proximal tubular cells.
recent reports have shown that mTORC1 activity is essential
to maintain podocyte homeostasis, but its hyperactivation is
a causes of glomerular lesion of both type 1 and type 2 dia-
betic nephropathy [68, 69]. Complete deletion of podocyte
mTORC1activityinpodocyte-speciﬁcRaptor-deﬁcientmice
causes podocyte injury [68]. In contrast, podocyte-speciﬁc
mTORC1 hyperactivation by podocyte-speciﬁc tuberous
sclerosis complex (TSC) 1-knockout mice show podocyte
injury and glomerular lesion similar to diabetic nephropathy
[69]. Finally, podocyte-speciﬁc Raptor-heterozygous mice
show partial deletion of mTORC1 activity in podocyte and
resistance to the development of diabetic nephropathy in
both STZ-induced type 1 diabetic mice [68]a n dt y p e2
diabetic db/db mice [69].
In addition to the above-mentioned function, inhibition
of autophagy is a main role of mTOR pathway [44, 58,
70]. Among the several signaling pathways that regulate
autophagy in mammalian cells, the classical pathway of
serine/threonine kinase, mTOR, plays a major role in the
negative regulation of autophagy because it integrates signals
that are emitted by growth factors, amino acids, glucose, and
energy status [71]. Autophagy is inhibited by the activation
of TOR under hypernutrient conditions [44, 58]. The
mTOR pathway involves two functional complexes: mTOR
complex 1 (mTORC1) and mTORC2. mTORC1, which
consists of the mTOR catalyticsubunit, regulatoryassociated
protein of mTOR (Raptor), G protein β-subunit-like protein
(GβL), proline-rich Akt substrate of 40kDa (PRAS40), and
DEP domain-containing mTOR-interacting protein (Dep-
tor) [72], is sensitive to the immunosuppressant rapamycin
[73, 74]. This complex regulates cell growth, metabolism (by
integrating amino acid and growth factor signals), energy,
and oxygen status [75]. The mTORC1 complex suppresses
autophagy via phosphorylation and inactivation of Ulk1,
an initiator of autophagosome formation [76]. Although
no direct evidences have been provided, hyperactivation of
mTOR pathway may suppress autophagy in podocyte and
tubular cells in diabetic condition. Furthermore, enhanced
activity of autophagy may be involved in the renoprotective
eﬀects of rapamycin treatment in diabetic nephropathy. The
mTORC2complexislesssensitivetorapamycinandincludes
mTOR, rapamycin-insensitive companion of mTOR (Ric-
tor), GβL, stress-activated protein kinase-interacting protein
1 (Sin1), protein observed with Rictor (PROTOR), and Dep-
tor [75, 77]. The mTORC2 complex regulates cytoskeletal
organization, metabolism, and cell survival [75, 78, 79].
However, until now, the role of mTORC2 in regulation of
autophagy has remained unclear.
5.2. AMPK. AMPK is activated under energy-depleted con-
ditionsandislikelytobesuppressedindiabeticnephropathy.
It has been reported that AMPK is inactivated (decreased
phosphorylation of AMPK) in glomeruli and tubules in
both type 1 and type 2 diabetic animal models [40, 81–
84], which are reversed by agents such as metformin and
resveratrolalongwithattenuationofdiabeticglomerularand
tubular injury [40, 85, 86]. This introduces the question
of how decreases in AMPK activity can be involved in the
pathogenesis of diabetic nephropathy. In type 1 and 2 dia-
betic kidneys, intrarenal lipid metabolism is altered, which isExperimental Diabetes Research 5
characterized by enhanced renal lipogenesis and suppressed
lipolysis [87–90]. AMPK-mediated phosphorylation inac-
tivates a lipogenic enzyme, acetyl-CoA carboxylase, which
results in decreased lipogenesis and enhanced lipolysis [91].
Decreases in renal AMPK activity in these mouse models
may be a mechanism of altered renal lipid metabolism and
subsequent lipotoxicity-associated renal damage. Since
AMPK can aﬀectvarious cellular metabolism as wells as lipid
metabolism [92, 93], the other molecular mechanism should
be involved in AMPK-mediated renoprotection.
AMPK plays a central role in the integration of several
stress stimuli and is a positive regulator of autophagy in re-
sponse to nutrient-depleted conditions. AMPK monitors the
energy status of the cell by sensing its AMP/ATP ratio [93].
Several upstream kinases, including liver kinase B1 (LKB1),
calcium/calmodulin kinase kinase (CaMKII) β,a n dT G F - β-
activated kinase-1 (TAK1), can activate AMPK by phospho-
rylating a threonine residue on its catalytic α subunit [93].
AMPK can crosstalk with the mTORC1 signal during multi-
ple steps of autophagy regulation. AMPK induces autophagy
by inhibiting mTORC1 activity via phosphorylation of its
regulatory-associated proteins [44, 58, 94]. Recent studies
have shown that AMPK-dependent phosphorylation of Ulk1
induces autophagy [94, 95]. A balance between mTORC1
and AMPK likely directly regulates Ulk1 activity and sub-
sequent autophagy initiation [44]. Thus, in addition to the
above-mentioned mechanism, AMPK-mediated induction
of autophagy may be involved in its renoprotection. AMPK
activation may be linked to autophagy for the maintenance
of renal homeostasis in diabetic kidney.
5.3. Sirt1. Sirtuins, the silent information regulator 2 family,
were originally identiﬁed as NAD+-dependent deacetylases
in experiments in lower species and consist of seven mem-
bers, Sirt1–Sirt7, in mammals [96, 97]. Sirtuins have been
identiﬁed as antiaging molecules under calorie-restricted
conditions and environmental stress. Some mammalian
sirtuins, especially Sirt1, have been shown to play important
roles in the regulation of aging, or in the pathogenesis of age-
relatedmetabolicdiseasessuchastype2diabetes[41,42,96].
An increase in the intracellular concentration of NAD+ by
caloricrestrictioncanactivateSirt1.Resultsthatdemonstrate
the role of Sirt1 in autophagy are still lacking compared
with those for mTOR and AMPK, but they have recently
been increasing. Sirt1 can deacetylate essential autophagic
factors such as Atg5, Atg7, and LC3 [98] and has been shown
to induce autophagy. Furthermore, Sirt1 deacetylates the
transcriptionfactorForkheadboxO3a(Foxo3a),whichleads
to enhanced expression of proautophagic BCL2/adenovirus
E1V 19-kDa interacting protein 3 (Bnip3) [26].
Renal expression of Sirt1 decreases in type 1 diabetic ani-
mal models [99, 100]. Also, reduced forms of nicotinamide
adenine dinucleotide (NADH) are metabolites of glucose
and fatty acids. Thus, NAD+/NADH ratios are decreased
in cells under conditions where nutrients are in excess,
such as diabetes. Sirt1-deacetylase activity should decrease in
diabetic nephropathy. Although direct renoprotective eﬀects
of Sirt1 in diabetic nephropathy have yet to be elucidated,
Sirt1 has shown renoprotective activity in aging kidneys and
ﬁbrotic kidney diseases. The previously mentioned ﬁndings
lead us to speculate that activation of Sirt1 should also have
therapeutic eﬃcacy in diabetic nephropathy. Furthermore,
Sirt1-induced autophagy activation may contribute to Sirt1-
mediated renoprotective eﬀect in diabetic nephropathy.
6. Regulation of Autophagy by
IntracellularStress
Besides nutrient stress, autophagy is upregulated by several
intracellular stresses, such as hypoxia, ROS, and ER stress
[44]. Based on recent reports, this process is probably a com-
pensatory response to maintain cell integrity. Furthermore,
these intracellular stresses have recently been focused on as
a pathogenesis of diabetic nephropathy, in addition to the
classical pathogenesis of diabetic nephropathy.
6.1. Oxidative Stress. Under conditions where nutrients are
in excess, such as diabetes and obesity, the production of
ROS in the kidneys is enhanced by high glucose concen-
trations [101, 102]. Furthermore, high levels of free fatty
acids, especially polysaturated fatty acids, also induce ROS
production in the kidneys [88, 103]. Oxidative stress is a
by-product of mitochondrial respiration and is associated
with cell dysfunction. Actually, a recent report has shown
abnormal mitochondrial morphology in diabetic kidney
[95, 104], suggesting that diabetic kidney fails to remove
damagedmitochondria. Thus,restoringtheabilitytocontrol
mitochondria homeostasis should be a therapeutic target of
diabetic nephropathy.
Mitochondrial quality control is mediated by mito-
chondrial autophagy (mitophagy) [105]. Similarly, oxidative
stress can induce autophagy to remove damaged mito-
chondria to protect cells. Thus, autophagy-mediated quality
control of mitochondria and subsequent reduction of ROS
should be essential to protect kidney in diabetic condition.
It has been reported that exogenous hydrogen peroxide
activates protein kinase RNA-like ER kinase (PERK), which
subsequently phosphorylates eukaryotic initiation factor-2α,
activates Atg4, and inhibits mTOR [106]. In response to
cellular stress or damage, mitochondrial membranes can be
permeabilized. The autophagic recognition of depolarized
mitochondria is mediated by a reﬁned voltage sensor, which
involves the mitochondrial kinase, phosphatase, and tensin
homolog-induced putative kinase 1.
6.2. Hypoxia. In early-stage diabetic nephropathy, hypoxia
is aggravated by manifestations of chronic hyperglycemic
abnormalities of red blood cells [107, 108], oxidative stress
[109], and diabetes mellitus-induced tubular apoptosis; as
such, tubulointerstitial hypoxia in diabetes mellitus might be
an important early event.
Hypoxia is also a stimulatory factor of autophagy.
Hypoxia-induced autophagy largely depends on hypoxia-
inducible factor-1α (HIF-1α) ,w h i c hi sat r a n s c r i p t i o nf a c t o r
that is activated and stabilized under hypoxic conditions6 Experimental Diabetes Research
Table 1: Autophagy-related kidney diseases.
Species and methods to monitor
autophagy Disease model Eﬀects of autophagy Reference
Sprague-Dawley rats,
immunohistochemistry of LC3 and
Western blotting of LC3-II
Cyclosporine A-induced
nephrotoxicity
Protection against tubular cell
death [80]
C57BL/6 mice, EM, and Western
blotting of LC3-II Cisplatin injury Protection against tubular cell
death [30]
C57BL/6 mice, EM,
immunoﬂuorescence of LC3, and
Western blotting of LC3-II
Aging Protection against aging and
hypoxia-related tubular damage [26]
GFP-LC3 mice Cisplatin injury Protection against tubular cell
death [31]
C57BL/6 mice, EM, and Western
blotting of LC3-II with 3-MA and
chloroquine
Ischemia reperfusion Protection against tubular cell
death [28]
Proximal tubular epithelial
cell-speciﬁc Atg5-deﬁcient mice Ischemia reperfusion Protection against tubular cell
death [29]
Podocyte-speciﬁc Atg5-deﬁcient mice
Aging, protein overload-, LPS-,
PAN-, and adriamycin-induced
glomerular injury
Protection against podocyte
injury [27]
EM: electron microscopy; GFP: green ﬂuorescent protein; 3-MA: 3-methladenine; Atg: autophagy-related genes; LPS: lipopolysaccharide; PAN: puromycin
aminonucleoside.
[110, 111]. HIF-1α activates transcription of Bnip3 and
Bnip3L and subsequently induces autophagy. Normally,
Beclin 1 interacts with Bcl-2 proteins. Bnip3 can disrupt
this interaction, liberating Beclin 1 from Bcl-2 in cells and
leading to autophagy. Thus, HIF1α-induced Bnip3 over-
expression promotes autophagy [112]. The transcription
of Bnip3 is also upregulated by the transcription factor
FOXO3, which is deacetylated and positively regulated by
Sirt1 [26]. Hypoxia causes damage to the mitochondria
and intracellular accumulation of ROS [113]. Removing
the damaged mitochondria under hypoxic conditions is
also an important role of Bnip3-mediated autophagy. Thus,
to investigate whether hypoxia-induced and Sirt1-mediated
autophagy is altered in diabetic kidney is interesting. If it
is altered, to restore autophagy activity even under diabetic
condition should be important to protect kidney form
hypoxia.
6.3.ERStress. ERstresshasrecentlybeenfocusedasapatho-
genesis of diabetic nephropathy. The induction of ER stress
and subsequent apoptosis by hyperglycemia and high levels
of free fatty acids (polysaturated fatty acids) are observed in
podocytes[114].Additionally,inproteinurickidneydiseases,
including diabetic nephropathy, massive proteinuria ﬁltered
from glomeruli causes ER stress responses and subsequent
apoptosis in renal tubular cells [14, 115]. Thus, to suppress
inadequate ER stress is thought as a therapeutic strategy of
diabetic nephropathy.
It is known that ER stress as well as hypoxia and ROS
also cause autophagy. The ER is not only involved in protein
synthesis and maturation but may also constitute a major
source/scaﬀold for the autophagic isolation membrane [47].
When misfolded proteins are not exported eﬃciently to
the cytoplasm and accumulate in the ER, the unfolded
protein response (UPR) is often induced [116–118]. The
UPR consists of three main branches that are controlled by
the ER membrane proteins: PERK; activating transcription
factor-6 (ATF6); inositol requiring enzyme 1 (IRE1) [116–
118]. Among these UPR-related proteins, PERK and ATF6
have been reported to induce autophagy [44]. PERK induces
the transcriptional activation of LC3 and Atg5 through
the action of the transcription factors ATF4 and CCAAT-
enhancer-binding protein homologous protein, respectively
[119]. It has been suggested that IRE1 is also involved in the
induction of autophagy by phosphorylation of Beclin 1 via
c-Jun NH2-terminal kinase-1 [44]. Enhanced and prolonged
ERstresscausesseveralpathogenicfeaturessuchasapoptosis
and inﬂammation [117, 118]. Thus, autophagy-mediated ER
degradation (ERphagy) may be required for cell protection
fromprolongedcytotoxicERstressshownindiabetickidney.
7.Autophagy inthe Kidneys
The study of autophagy has previously been undertaken in
lowerspecies.Thestudyofautophagyinmammaliansystems
is advancing rapidly and has revealed that mammalian
autophagy is involved in the pathogenesis of various met-
abolic or age-related diseases [18–27].
Recently, nephrologists have also entered this exciting
ﬁeld of study. In this section, we review recent studies on
the pathophysiology of autophagy in the kidneys. Autophagy
has been observed in various parts of the kidneys, including
proximal tubules,andthick ascending limbs. Inparticular, in
podocytes, higher levels of constitutive autophagy have beenExperimental Diabetes Research 7
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Figure 4: Regulation of autophagy by nutrient and intracellular stresses and the relationship between autophagy and the progression of diabetic
nephropathy. Under normal conditions, intracellular stresses such as hypoxia, mitochondrial ROS, and ER stress induce autophagy. Nutrient
depletion enhances autophagy by inhibiting mTORC1 and by activating AMPK and Sirt1. This activation of autophagy helps to maintain
intracellular homeostasis and may have renoprotective eﬀects. In contrast, under diabetic conditions, high glucose or FFA levels increase
intracellular stresses, leading to the progression of diabetic nephropathy. Furthermore, nutrient excess and high glucose levels under diabetic
conditions inhibit autophagy by inhibiting AMPK and Sirt1, and by activating mTORC1. This inactivation of autophagy may reinforce the
progression of diabetic nephropathy. ROS: reactive oxygen species; ER: endoplasmic reticulum; mTORC1: mammalian target of rapamycin
(mTOR) complex 1 (mTORC1); AMPK: AMP-activated protein kinase; FFA: free fatty acid.
observed using GFP-LC3 transgenic mice even under normal
conditions [27]. As for the role of autophagy in renal patho-
physiology, several researchers have reported the signiﬁcance
of autophagy in experimental renal injury models. In several
experimental animal models of glomerulonephritis, includ-
ing puromycin aminonucleoside and adriamycin-induced
proteinuria, autophagy has been identiﬁed and shown to
play renoprotective and antiproteinuric roles in podocytes
through the use of podocyte-speciﬁc Atg5 knockout mice
[27].Ithasbeenrecentlyreportedthatthenormalagingpro-
cess suppresses autophagy in podocytes, and that podocyte-
speciﬁc deletion of Atg5 leads to glomerulopathy in aging8 Experimental Diabetes Research
mice that is accompanied by accumulation of oxidized and
ubiquitinated proteins, ER stress, and proteinuria [27].
In renal tubules as well as in podocytes, autophagy has
been reported to play a renoprotective role under several
pathologicalconditions.Inrenalischemia-reperfusioninjury
models,theupregulationofautophagytoprotectthekidneys
was observed using 3-MA, chloroquine [28], and proximal
tubular epithelial cell-speciﬁc Atg5 knockout mice [29]. Ad-
ditionally, in cisplatin-induced acute kidney injury models,
the increase of autophagosomes was observed by EM, LC3-II
Western blotting [30], and GFP-LC3 transgenic mice [31].
Hypoxia is one of the causes of renal tubular damage in
aged kidney [120]. We have previously shown that hypoxia-
induced autophagy activity declined with age, which led to
accumulations of damaged mitochondria and mitochondrial
ROS in the kidney [26]. Interestingly, long-term calorie
restriction (CR) restored autophagy activity even in aged
kidney [26]. As a mechanism, Sirt1-mediated autophagy was
essentialinCR-mediatedrenoprotectioninagedkidney[26].
Bnip3 expression is essential to induce autophagy under
hypoxic condition [121] and is positively regulated by a
transcriptional factor Foxo3a [122]. This regulation was
alteredinagedkidney.Ontheotherhand,CR-mediatedSirt1
activation deacetylated and activated Foxo3a transcriptional
activity and subsequent Bnip3-mediated autophagy even in
aged kidney [26]. Furthermore, the kidney of heterozygous
Sirt1-knockout mice showed lower autophagy activity along
with the decrease in Bnip3 expression, and thus they were
resistant to CR-mediated antiaging eﬀects [26]. This ﬁnding
suggests that Sirt1 is essential for CR-mediated renoprotec-
tion.
Thus, accumulative evidence has demonstrated the pa-
thophysiological importance of autophagy in the kidneys
(Table 1). However, the role and existence of autophagy in
other types of renal cells besides podocytes and proximal tu-
bular cells is not known.
8.Perspective
It is evident that the above-mentioned nutrient-sensing sig-
nals exist in the kidneys. However, what are their physio-
logical roles in this organ? The kidneys require suﬃcient
amounts of ATP for maintenance of their functions and
avidly consume oxygen to drive mitochondrial oxidative
phosphorylation among major organs. A small percentage of
oxygen consumed by mitochondria is incompletely reduced
to ROS, and this unremitting generation of oxidants during
mitochondrial respiration, albeit in small amounts, may
cumulatively damage the kidneys, which are heavily de-
pendent on mitochondrial metabolism. Regulating mito-
chondrial metabolism in response to nutrient conditions via
regulation of autophagy that can remove damaged mito-
chondria and subsequent ROS may be a physiological role
of renal nutrient-sensing signals.
Autophagy is regulated by nutrient conditions, and its
alteration associates with various metabolic and age-as-
sociated diseases.Althoughstudieson autophagyhavemeth-
odological limitations, as outlined above, it is evident that
autophagydeﬁciencyisassociatedwithpodocyteandtubular
cell injuries from the studies using Atg5-knockout mice [27,
29]. These ﬁndings lead us to hypothesize that autophagy is
altered in diabetic kidneys, and autophagy deﬁciency should
contribute to the pathogenesis of diabetic nephropathy.
Alterednutrient-sensingsignalsindiabetickidneysmaycon-
tribute to accumulation of mitochondrial ROS via suppres-
sion of autophagy, which may be associated with initiation
of the early stages of diabetic nephropathy. Both hypoxia and
proteinuria-inducedERstresscontributetoproximaltubular
cell damage in the progressive and overt stages of diabetic
nephropathy. Why do diabetic kidneys show a weakness
against these stresses? How can we protect the kidneys
from these stresses even under diabetic conditions? One an-
swer may be derived from autophagy studies. Autophagy
deﬁciency in diabetic kidneys may make tubular cells fragile
under hypoxic and ER stress and possibly lead to progression
of diabetic nephropathy (Figure 4). Activation of autophagy
may be a therapeutic option for the advanced stages of
diabetic nephropathy.
9. Concluding Comments
In recent decades, numerous investigators have been making
eﬀorts to identify the molecular mechanisms involved in
the initiation and progression of diabetic nephropathy to
develop new therapeutic strategies. However, end-stage renal
disease due to diabetic nephropathy continues to increase
worldwide. There is an urgent need to identify additional
new therapeutic targets for prevention of diabetic nephropa-
thy. We have provided a perspective on whether autophagy
is involved in the pathogenesis of diabetic nephropathy
and whether it is an acceptable new therapeutic target.
Unfortunately, there have still not been many studies that
have focused on autophagy in diabetic nephropathy. In the
next few years, studies using Atg-gene knockout/knockdown
mice combined with diﬀerent methodologies will elucidate
this possibility. Finally, these studies will ultimately give us
a clearer perspective as to whether autophagy should be con-
sidered as a novel therapeutic target to halt the progression
of diabetic nephropathy.
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